Incyte Corporation

$59.16
(as of Apr 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Incyte Corporation

Stock Price
$59.16
Ticker Symbol
INCY
Exchange
NASDAQ

Industry Information for Incyte Corporation

Sector
Healthcare
Industry
Biotechnology

Company Description for Incyte Corporation

Country
USA
Full Time Employees
2,617

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Fundamentals for Incyte Corporation

Market Capitalization
$11,448,880,128
EBITDA
$177,596,992
Dividends per Share
P/E Ratio
394.4
Forward P/E Ratio
9.78
Earnings per Share
$0.15
Earnings per Share Estimate Next Year
Profit Margin
0.77%
Shares Outstanding
193,524,000
Percent Owned by Insiders
2.08%
Percent Owned by Institutions
97.05%
52-Week High
52-Week Low

Technical Indicators for Incyte Corporation

50-Day Moving Average
200-Day Moving Average
RSI
45.33
2.35

Analyst Ratings for Incyte Corporation

Strong Buy
10
Buy
2
Hold
14
Sell
1
Strong Sell
0

News About Incyte Corporation

Apr 25, 2025, 9:00 AM EST
Two factors often determine stock prices in the long run: earnings and interest rates. See more.
Apr 25, 2025, 8:00 AM EST
WILMINGTON, Del., April 25, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. See more.
Apr 24, 2025, 10:01 AM EST
Blueprint Medicines (BPMC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. See more.
Apr 24, 2025, 9:08 AM EST
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. See more.